安罗替尼+卡瑞利珠单抗联合放疗治疗晚期非小细胞肺癌的疗效  

Efficacy of anlotinib+camrelizumab combined with radiotherapy in treatment of advanced non-small cell lung cancer

作　　者：黄骞 徐菊娣 杨志勇 倪国英 黄燕 梁洪享 黄英 HUANG Qian;XU Judi;YANG Zhiyong;NI Guoying;HUANG Yan;LIANG Hongxiang;HUANG Ying(Department of Oncology,Chongming Hospital Affiliated to Shanghai University of Medicine&Health Sciences,Shanghai 202150,China)

机构地区：[1]上海健康医学院附属崇明医院肿瘤科,上海202150

出　　处：《中国临床研究》2025年第3期371-374,共4页Chinese Journal of Clinical Research

基　　金：上海市卫生健康委员会科研课题(201940274);上海市崇明区“可持续发展科技创新行动计划”项目(CKY2020-19,CKY2021-06)。

摘　　要：目的 探讨安罗替尼+卡瑞利珠单抗联合放疗治疗晚期非小细胞肺癌(NSCLC)的安全性及其对血清肿瘤标志物的影响。方法 选取2020年7月至2021年7月于上海健康医学院附属崇明医院接受诊治的晚期NSCLC患者96例作为研究对象,按照随机数字表法分为A组(予以安罗替尼+卡瑞利珠单抗联合放疗)、B组(予以卡瑞利珠单抗联合放疗)及C组(予以放疗),各32例。治疗4个周期后对比3组疾病控制率(DCR)、客观缓解率(ORR)、癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)、毒副反应,随访至2023年8月,对比3组生存情况。结果 A组的ORR、DCR均高于B组和C组(P<0.05)。治疗后,A组的CEA、CA125、CYFRA21-1低于B组和C组(P<0.05)。三组毒副反应发生率比较,差异无统计学意义(χ^(2)=0.667,P=0.716)。A组的2年生存率(81.25%)高于B组(56.25%)和C组(50.00%),且生存时间[(21.75±5.08)个月]长于B组[(18.47±7.00)个月]和C组[(17.13±8.13)个月](P<0.05)。结论 安罗替尼+卡瑞利珠单抗联合放疗治疗效果好,不仅能降低血清肿瘤标志物表达水平,而且能延长患者生存时间。Objective To investigate the safety of anlotinib+camrelizumab combined with radiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and its effect on serum tumor markers.Methods Ninety-six patients with advanced NSCLC who were diagnosed and treated at Chongming Hospital Affiliated to Shanghai University of Medicine&Health Sciences from July 2020 to July 2021 were selected as study subjects.They were divided into group A(receiving anlotinib+camrelizumab combined with radiotherapy,n=32),group B(receiving camrelizumab combined with radiotherapy,n=32)and group C(receiving radiotherapy,n=32)according to random number table method.After 4 cycles of treatment,disease control rate(DCR),objective response rate(ORR),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment(CYFRA21-1),and toxicity were compared among three groups,and survival were compared until follow up to August 2023.Results The ORR and DCR of group A were higher than those of group B and group C(P<0.05).After treatment,CEA,CA125 and CYFRA21-1 in group A were lower than those in group B and group C(P<0.05).There was no significant difference in the incidence of toxic and side effects among the three groups(χ^(2)=0.667,P=0.716).The 2-year survival rate(81.25%)in group A was higher than that in group B(56.25%)and group C(50.00%),and the survival time[(21.75±5.08)months]was longer than that in group B[(18.47±7.00)months]and group C[(17.13±8.13)months](P<0.05).Conclusion Anlotinib+camrellizumab combined with radiotherapy has a relatively ideal effect,which can not only reduce the expression levels of serum tumor markers,but also prolong the survival time of patients.

关 键 词：安罗替尼 卡瑞利珠单抗 靶向治疗 放射治疗 免疫治疗 晚期非小细胞肺癌 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]